Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/FDA starts review of wellness peptides, boosting Hims & Hers shares over 8%.

HIMS

$37.02

-$0.15 -0.40%

FDA starts review of wellness peptides, boosting Hims & Hers shares over 8%.

Market News

16 Apr 2026

Proactive Investors

View Source

Bullish

The FDA has initiated a formal review process for several wellness peptides used in compounding pharmacies, including BPC-157 KPV and TB-500. This move caused Hims & Hers Health shares to rise over 8%, reflecting investor optimism about potential regulatory changes. Bank of America raised its price target for the company, citing increased long-term opportunities tied to these peptide developments. However, the review is an early procedural step, and it remains uncertain whether these peptides will be approved for broader use, meaning the impact on earnings is not immediate but could enhance strategic options in the future.

More News (HIMS)

Law firm investigates Hims & Hers for allegedly sharing users' private health data without consent.

Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...

Market News

Bearish

15 hours ago